6 ph level in urine

BOISE, Idaho — Freshman wide receiver George Dimopoulos threw a 25-yard touchdown pass to Dane Pardridge on the first play of double overtime and Jordan Hansen ended the game on a fourth-down sack to give Northern Illinois a 28-20 victory over Fresno State on Monday in the Idaho Potato Bowl. Dimopoulos, who played quarterback in high school, also converted the two-point conversion when he passed it to quarterback Josh Holst for his second completion of the season. Holst, a freshman walk-on, was making just his third start at quarterback as NIU was without starter Ethan Hampton, who entered with 1,600 yards and 12 touchdowns to go with six interceptions. Holst completed 18 of 30 passes for 182 and two touchdowns for Northern Illinois (8-5). He was also intercepted on the first play of the game. Both teams missed a 35-yard field goal in the final three minutes of regulation, including Dylan Lynch’s third miss of the game on the final play to send it to overtime. Fresno State started overtime with a touchdown when Bryson Donelson was left wide open out of the backfield to haul in a 9-yard touchdown pass. NIU needed five plays, and a defensive holding penalty, to score as Holst found Grayson Barnes for a 3-yard touchdown. Donelson finished with 15 carries for 82 yards and a touchdown for Fresno State (6-7). He added three catches for 28 yards and another score. Dual-threat quarterback Joshua Wood was 16 of 23 for 180 yards and a touchdown. Mac Dalena made six catches for 118 yards to help go over 1,000 yards for the season. Fresno State was without 14 players, including starting quarterback Mikey Keene after he transferred to Michigan. Two top-three receivers, Jalen Moss and Raylen Sharpe, also did not play as the Bulldogs were forced to use five new starters. UTSA 44, COASTAL CAROLINA 15: Owen McCown threw for 254 yards and a touchdown and UTSA scored the opening 27 points of the Myrtle Beach Bowl to cruise past short-handed Coastal Carolina in Conway, S.C. UTSA (7-6) broke away in the second quarter by scoring a touchdown on three straight drives for a 21-0 lead. McCown was 14 of 17 in the first half, including a 6-yard touchdown pass to Patrick Overmyer. McCown also scored on a 35-yard run after breaking two tackles near the end zone. The other score was a 9-yard touchdown run by Brandon High. Coastal Carolina (6-7) finished the first half with just 140 total yards — 60 coming on the final drive. The Chanticleers punted on five straight drives to begin the game — with the longest possession lasting seven plays for 25 yards. UTSA added short field goals on its opening two drives of the second half, while Coastal Carolina started with two straight three-and-out drives. UTSA ended CCU’s third drive on Jakevian Rodgers’ first career interception to extend the program’s single-game streak with an interception and a sack to 23 games. CCU’s first touchdown came on the first play of the fourth quarter when Bryson Graves caught a 50-yard touchdown pass from Tad Hudson. But UTSA’s Chris Carpenter returned the ensuing kickoff for a 93-yard touchdown to make it 34-7. It was the largest margin of victory in the five-year history of the Myrtle Beach Bowl. Get local news delivered to your inbox!CALGARY, AB, Dec. 3, 2024 /CNW/ - Enbridge Inc. (TSX: ENB) (NYSE: ENB) is pleased to announce that its Board of Directors has appointed Douglas L. Foshee as a Director of Enbridge, effective January 1, 2025. Mr. Foshee has more than 40 years of energy industry experience, including as Chair, President and CEO of El Paso Corporation from 2003 to 2012, as CFO and then COO of Halliburton Company from 2001 to 2003, and as Chair, President and CEO of Nuevo Energy from 1996-2001. "On behalf of the Board of Directors of Enbridge, we are very pleased to welcome Doug to the Enbridge Board. He has extensive energy industry and business experience and will be an excellent addition to our Board," stated Pamela Carter, the Chair of the Board of Directors of Enbridge. About Enbridge Inc. At Enbridge, we safely connect millions of people to the energy they rely on every day, fueling quality of life through our North American natural gas, oil and renewable power networks and our growing European offshore wind portfolio. We're investing in modern energy delivery infrastructure to sustain access to secure, affordable energy and building on more than a century of operating conventional energy infrastructure and two decades of experience in renewable power. We're advancing new technologies including hydrogen, renewable natural gas, carbon capture and storage. Headquartered in Calgary, Alberta, Enbridge's common shares trade under the symbol ENB on the Toronto (TSX) and New York (NYSE) stock exchanges. To learn more, visit us at enbridge.com . FOR FURTHER INFORMATION PLEASE CONTACT: Media Toll Free: (888) 992-0997 Email: media@enbridge.com Investment Community Toll Free: (800) 481-2804 Email: investor.relations@enbridge.com View original content: https://www.prnewswire.com/news-releases/enbridge-appoints-new-director-to-its-board-302321529.html SOURCE Enbridge Inc.COLLEGE BOWL

$HAREHOLDER ALERT: The M&A Class Action Firm Continues To Investigate Merger - AVTE, BCOV, ...COLLEGE BOWLSamsung Electronics' chip production line in Pyeongtaek, Gyeonggi Province / Courtesy of Samsung Electronics Broadcom's rise may provide new opportunity for chipmakers The outlook for fourth-quarter earnings at Samsung Electronics and SK hynix is clouded by a negative market environment, driven by sluggish demand for information technology (IT) devices, and falling prices for legacy DRAM chips. According to market tracker FnGuide, brokerages estimate Samsung Electronics' operating profit for the fourth quarter at 9.22 trillion won ($6.3 billion) as of Wednesday, a decrease of nearly 5 percent from 9.7 trillion won a month earlier. Throughout this month, local brokerages have been revising their estimates for Samsung’s operating profit, citing an oversupply of legacy memory chips due to sluggish demand for IT devices and undercutting by Chinese firms. “In (the) fourth quarter, the memory market faces challenges stemming from excessive inventory in the chips for PC and mobile devices, necessitating further price cuts to boost shipping volumes,” iM Securities analyst Song Myung-sub said, lowering his estimation for the company’s fourth-quarter operating profit to 8.3 trillion won from 9.9 trillion won. “Consequently, chances are high for Samsung's memory shipment volumes or average selling prices falling short of current market expectations.” According to DRAMeXchange, the average price of a DDR4 8GB 1Gx8 memory module, which is mostly used in PCs, dropped by 35.7 percent from $2.10 in July to $1.35 in November. Market observers attribute the price drop to undercutting by Chinese memory manufacturers, with companies like CXMT and JHICC supplying DDR4 8GB chips at prices between $0.75 and $1. The slowdown in the legacy DRAM business is impacting Samsung more significantly, as high-bandwidth memory (HBM) chips, which are in increasing demand for artificial intelligence (AI) processors, still account for only a small share of the company's earnings. “Samsung’s DRAM business is expected to underperform the market estimation because of delays in supplying HBM3e chips for Nvidia, CXMT’s undercutting and deteriorating supply and demand conditions for legacy DRAM chips,” Kiwoom Securities analyst Park Yoo-ak said. SK Group Chairman Chey Tae-won, left, listens to an official at SK hynix's high-bandwidth memory chip production line in Icheon, Gyeonggi Province, Aug. 5. Courtesy of SK Group Although the situation is slightly better for SK hynix, which now stands as the world’s top supplier of HBM, the market is also lowering its estimation for the company’s fourth-quarter earnings due to the sluggish legacy chip market. The market consensus for SK hynix’s fourth-quarter earnings was 8.05 trillion won as of Wednesday, down 1.2 percent from 8.15 trillion won a month earlier. “Samsung Electronics and SK hynix will be able to rebound after showcasing sluggish performances in the fourth quarter of this year,” DAOL Investment & Securities analyst Ko Young-min said. The market expects that the two chipmakers will accelerate their transition efforts toward HBM to cope with the growing demand for AI processors. Speculation is also rising that U.S.-based Broadcom is turning to the two Korean firms to secure HBM4, which will be produced starting next year, for its AI application-specific integrated circuits (ASIC). The Korea Economic Daily reported earlier this week that SK hynix received Broadcom’s request for HBM4 and has begun developing the prototype. Samsung Electronics also initiated discussions with Broadcom over HBM4 supplies. Given that Nvidia has already secured most of the HBM chips that SK hynix will produce next year, industry officials expect that Samsung may cover orders from Broadcom. While graphics processing units, or GPUs, like those used in Nvidia’s AI processors, offer more versatility for general computing, ASICs are more efficient for specialized tasks and are typically priced lower than GPUs. To remove this article -

COLLEGE BOWL

The United States on Saturday announced a new $988 million security assistance package for Ukraine as Washington races to provide aid to Kyiv before President-elect Donald Trump takes office. Trump's November election victory has cast doubt on the future of American aid for Ukraine, providing a limited window for billions of dollars in already authorized assistance to be disbursed before he is sworn in next month. The package features drones, ammunition for precision HIMARS rocket launchers, and equipment and spare parts for artillery systems, tanks and armored vehicles, the Pentagon said in a statement. Trump met in Paris earlier Saturday with Ukrainian President Volodymyr Zelensky, who said any resolution of the war with Russia should be a "just" settlement that includes "strong security guarantees for Ukraine." The meeting was of huge importance to Zelensky, given fears in Kyiv that Trump may urge Ukraine to make concessions to Moscow. The latest aid will be funded via the Ukraine Security Assistance Initiative, under which military equipment is procured from the defense industry or partners rather than drawn from American stocks, meaning it will not immediately arrive on the battlefield. It follows a $725 million package announced on Monday that included a second tranche of landmines as well as anti-air and anti-armor weapons. The outgoing administration of President Joe Biden is working to get as much aid as possible to Ukraine before Trump -- who has repeatedly criticized US assistance for Kyiv and claimed he could secure a ceasefire within hours -- takes over. Trump's comments have triggered fears in Kyiv and Europe about the future of US aid, and Ukraine's ability to withstand Russian attacks in the absence of further American support. "Our job has been to try and put Ukraine in the strongest possible position on the battlefield so that it is in the strongest possible position at the negotiating table," National Security Advisor Jake Sullivan said Saturday. In the closing weeks of Biden's term, the goal is "a massive surge of assistance and to up the economic pressure on Russia," he said. - America 'weaker' alone - US Defense Secretary Lloyd Austin on Saturday warned that failure to continue opposing Russia's actions would have dire consequences. "We can continue to stand up to the Kremlin. Or we can let (Russian President Vladimir) Putin have his way -- and condemn our children and grandchildren to live in a world of chaos and conflict," said Austin, who like Sullivan was speaking at the Reagan National Defense Forum in California. "This administration has made its choice. And so has a bipartisan coalition in Congress. The next administration must make its own choice." The defense chief also emphasized the importance of US allies and partners in his remarks -- a contrast to Trump's go-it-alone "America first" world view. "Here is the stark military fact: our allies and partners are huge force multipliers," Austin said. "Ultimately, America is weaker when it stands alone. And America is smaller when it stands apart," he said. "There is no such thing as a safe retreat from today's interwoven world." The United States has spearheaded the push for international support for Ukraine, quickly forging a coalition to back Kyiv after Russia launched its full-scale invasion in 2022 and coordinating aid from dozens of countries. Ukraine's international supporters have since then provided tens of billions of dollars in weapons, ammunition, training and other security aid that has been key to helping Kyiv resist Russian forces. wd/mlm/acb

The Philadelphia Eagles clinched the NFC East division title on Sunday, handing the Dallas Cowboys a humiliating 41-7 defeat while the Buffalo Bills secured the second seed in the AFC with a 40-14 crushing of the New York Jets. The Cowboys were already eliminated from playoff contention and without top receiver CeeDee Lamb with a shoulder injury, but it was their defense that struggled. Eagles starting quarter-back Jalen Hurts missed the game due to concussion. Kenny Pickett got the start but had to leave the game in the third quarter with a rib injury with Philadelphia 24-7 up. That meant third-choice Tanner McKee took over under the center and two of his four passes were for touchdowns. The real damage to the Cowboys, who gave up four turnovers, was done by the Eagles star running back Saquon Barkley who put up 167 yards on 31 carries to pass the 2,000 yard mark for the season. Barkley, who has 2,005 yards needs to put up 101 yards next week to break Eric Dickerson's record for the most rushing yards in a season, set for the Los Angeles Rams in 1984. The win means the Eagles are guaranteed at least the number two seed in the NFC. The Bills take the second seed in the AFC, behind the Kansas City Chiefs, after taking care of business against the New York Jets. The Bills led 12-0 at the half before their quarterback Josh Allen took total control of the game with touchdown passes to Amari Cooper and Keon Coleman either side of a rushing score from James Cook. Allen, who threw for 182 yards, had opened the scoring with a one-yard rush. Jets quarterback Aaron Rodgers threw two interceptions and was sacked four times. The Indianapolis Colts were eliminated from playoff contention after falling 45-33 to the 3-13 New York Giants. While the Giants had nothing to play for, quarterback Drew Lock enjoyed himself -- he matched his career high of four touchdown passes and rushed for another score as the Giants ended their 10-game losing streak. The Tampa Bay Buccaneers kept their post-season hopes alive as Baker Mayfield threw for 359 yards and five touchdowns in a 48-14 rout of the Carolina Panthers. Later on Sunday, the Minnesota Vikings, searching for the top seed in the NFC, take on NFC North divisional rivals the Green Bay Packers. The Washington Commanders would book a playoff berth if they can beat the Atlanta Falcons in Sunday night's game. sev/bb

NoneCARSON, Calif. — The LA Galaxy finished 26th in the 29-team Major League Soccer standings just one season ago, and their biggest supporters boycotted certain matches to protest a decade of poor performance. The most successful club in league history seemed light years away from its luminous prime. When the Galaxy raised the MLS Cup again Saturday amid confetti and fireworks, their spectacular transformation was complete. In only one year, a team that was profoundly lost had rediscovered its peerless championship pedigree. "We won this trophy, and it's finally back where it belongs," striker Dejan Joveljic said. Joseph Paintsil and Joveljic scored in the first half, and the Galaxy won their record sixth MLS Cup championship with a 2-1 victory over the New York Red Bulls. After striking twice in the first 13 minutes of the final, the Galaxy nursed their lead through a scoreless second half to raise their league's biggest trophy for the first time since 2014. MLS' most successful franchise struggled through most of the ensuing years, but everything changed after LA spent smartly in the offseason to build a high-scoring new lineup topped by Paintsil, Joveljic and Gabriel Pec. The Galaxy finished second in the Western Conference and streaked through the postseason with an MLS playoff-record 18 goals in five games to win another crown. "I'm just so proud of this group after the challenges that we (had) and the way they bounced back and competed as a group," Galaxy coach Greg Vanney said. "We spent a lot of energy at the start, but I'm just so proud of these guys. They've cemented themselves as legends in this club." The Galaxy even won this title without perhaps their most important player. Riqui Puig, the playmaking midfielder from Barcelona who ran their offense impressively all season long, tore a ligament in his knee last week in the conference final. Puig watched this game in a suit, but the Catalan catalyst's teammates hadn't forgotten him: After his replacement, Gastón Brugman, set up LA's opening goal with a superb pass in the ninth minute, Paintsil held up Puig's jersey to their roaring fans during the celebration. "I was really waiting for this moment," said Paintsil, who scored his 14th goal of an impressive season. "I'm much more, 10 times faster than them, and Gaston saw the space. ... It was really a good thing. We did it for Riqui, and we did it for our family that came, and our supporters." Just four minutes later, Joveljic sprinted past four New York defenders and chipped home his 21st goal. Brugman was named the MLS Cup MVP after a commanding performance in midfield. The Uruguayan hadn't started a match for the Galaxy since Oct. 5 after an injury-slowed season, playing only as a postseason substitute before the final. "I dreamed of that yesterday, of something I could give to the team," Brugman said of his pass to Paintsil. "Today, it happened." Sean Nealis scored for the seventh-seeded Red Bulls, whose improbable postseason charge ended one win shy of their first Cup championship. With the league's youngest roster, New York fell just short of becoming the lowest-seeded team to win the tournament under first-year German coach Sandro Schwarz. "I love these guys," Schwarz said. "Some guys, they are crying. In the big picture, that's a start. Sometimes when you lose the final, it's tough, but you use this experience to create the next energy, the next intensity." Galaxy goalkeeper John McCarthy made four saves to win his second MLS title in three seasons, but Nealis beat the 2022 MLS Cup MVP in the 28th minute when he volleyed from the penalty area. The second half was lively: Red Bulls captain Emil Forsberg hit the outside of the post in the 72nd minute, while Pec and Galaxy substitute Marco Reus nearly converted chances a few moments later. The ball got loose in the Galaxy's penalty area in the third minute of extra time, but two Red Bulls couldn't finish. After Galaxy owner Phil Anschutz received the MLS Cup that bears his name because of his steady financial support of the league during its shaky years, Galaxy captain Maya Yoshida carried the trophy to his teammates for the celebration. The Galaxy extended their lead over DC United (4) for the most MLS Cup championships in league history. The Red Bulls remain one of three original MLS franchises never to win the title, along with FC Dallas and the New England Revolution. The Galaxy finished 17-0-3 this season at their frequently renamed suburban stadium, where the sellout crowd of 26,812 for the final included several robust cheering sections of Red Bulls supporters hoping to see their New Jersey-based club's breakthrough. But this season was about the Galaxy's rebirth. The club famous for employing global stars from David Beckham and Zlatan Ibrahimovic to Robbie Keane and Javier "Chicharito" Hernández swiftly turned itself into a contender again by acquiring young talents without international fame. The Galaxy signed Pec from Brazil and grabbed Paintsil, a Ghanaian playing in Belgium. The duo combined with Joveljic to form a potent attack with orchestration from Puig, one of MLS' best players. "Losing a guy like Riqui after the performance he put in all season was devastating," McCarthy said. "Even if he wasn't on the field, we did it for him."Israeli Prime Minister Benjamin Netanyahu underwent successful surgery Sunday to have his prostate removed, hospital officials said, a procedure that came as he manages multiple crises including the war in Gaza and his trial for alleged corruption. Netanyahu, who has had a series of health issues in recent years, has gone to great lengths to bolster a public image of himself as a healthy, energetic leader. During his trial this month, he boasted about working 18-hour days, accompanied by a cigar. But as Israel's longest-serving leader, such a grueling workload over a total of 17 years in power could take a toll on his well-being. Netanyahu, 75, is among older world leaders including U.S. President Joe Biden, 82, President-elect Donald Trump, 78, Brazil's President Luiz Inacio Lula da Silva, 79, and Pope Francis, 88, who have come under scrutiny for their age and health issues. Netanyahu's latest condition is common in older men, but the procedure has had some fallout. The judges overseeing his trial accepted a request Sunday from his lawyer to call off three days of testimony scheduled this week. The lawyer, Amit Hadad, had argued that Netanyahu would be fully sedated for the procedure and hospitalized for “a number of days.” Jerusalem's Hadassah Medical Center announced late Sunday that the procedure had been “completed successfully.” Justice Minister Yariv Levin, a close ally, served as acting prime minister during the operation. Netanyahu is expected to remain hospitalized for several days. With so much at stake, Netanyahu’s health in wartime is a concern for both Israelis and the wider world. A turbulent time in the region As Israel’s leader, Netanyahu is at the center of major global events that are shifting the Middle East. With the dizzying pace of the past 14 months, being incapacitated for even a few hours can be risky. Netanyahu will be in the hospital at a time when international mediators are pushing Israel and Hamas to reach a ceasefire in Gaza and as fighting between Israel and Yemen’s Iran-backed Houthi rebels intensifies. Prostate issues are common and, in many cases, easily treatable. Still, the procedure puts a dent in Netanyahu’s image of vigor at a time when he would want to project strength more than ever, both to an Israeli audience navigating constant threats as well as to Israel’s enemies looking to expose its weaknesses. Previous health issues, include a heart condition Netanyahu insists he is in excellent health. His office releases footage of him touring war zones in full protective gear flanked by military officers, or meeting with defense officials on windswept hilltops in youthful dark shades and puffer jackets. But that image was shattered last year when Netanyahu’s doctors revealed that he had a heart condition, a problem that he had apparently long known about but concealed from the public. A week after a fainting spell, Netanyahu was fitted with a pacemaker to control his heartbeat. Only then did staff at the Sheba Medical Center reveal that Netanyahu has for years experienced a condition that can cause irregular heartbeats. The revelation came as Netanyahu was dealing with massive anti-government protests. The news about a chronic heart problem stoked further anger and distrust during extreme political polarization in Israel. Last year, Netanyahu was rushed to the hospital for what doctors said likely was dehydration. He stayed overnight, prompting his weekly Cabinet meeting to be delayed. Earlier this year, Netanyahu underwent hernia surgery, during which he was under full anesthesia and unconscious. Levin served as acting prime minister during the operation. Recovery can be quick According to Netanyahu’s office, the Israeli leader was diagnosed with a urinary tract infection Wednesday stemming from a benign enlargement of his prostate. The infection was treated successfully with antibiotics, but doctors said the surgery was needed in any case. Complications from prostate enlargement are common in men in their 70s and 80s, Dr. Shay Golan, head of the oncology urology service at Israel’s Rabin Medical Center, told Israeli Army Radio. Golan spoke in general terms and was not involved in Netanyahu’s care or treatment. He said an enlarged prostate can block proper emptying of the bladder, leading to a build-up of urine that can lead to an infection or other complications. After medicinal treatment, doctors can recommend a procedure to remove the prostate to prevent future blockages, Golan said. In Netanyahu’s case, because the prostate is not cancerous, Golan said doctors were likely performing an endoscopic surgery, carried out by inserting small instruments into a body cavity, rather than making surgical cuts in the abdomen to reach the prostate. The procedure lasts about an hour, Golan said, and recovery is quick. He said that aside from catheter use for one to three days after the procedure, patients can return to normal activity without significant limitations.

HOUSTON (AP) — Addison Patterson's 25 points helped Northwestern State defeat Houston Christian 64-57 on Saturday night. Patterson also added five rebounds and three steals for the Demons (5-5, 2-0 Southland Conference). Jon Sanders shot 5 of 9 from the field, including 2 for 4 from 3-point range, and went 5 for 5 from the line to add 17 points. Willie Williams shot 5 of 6 from the field to finish with 10 points, while adding 11 rebounds. Bryson Dawkins finished with 13 points for the Huskies (3-7, 1-1). D'Aundre Samuels added nine points for Houston Christian. Julian Mackey also had nine points. The Associated Press created this story using technology provided by Data Skrive and data from Sportradar .2024: Homicides at five-year low, domestic violence up in EdmontonDublin, Dec. 23, 2024 (GLOBE NEWSWIRE) -- The "Burkitt Lymphoma - Global Clinical Trials Review, 2024" has been added to ResearchAndMarkets.com's offering. The clinical trial report provides an overview of Burkitt Lymphoma Clinical trials scenario. This report provides top line data relating to the clinical trials on Burkitt Lymphoma. The report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. The report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. The clinical trials database undergoes periodic update by dynamic process. The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage. Report Scope The report provides a snapshot of the global clinical trials landscape Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment The Report provides enrollment trends for the past five years Report provides latest news for the past three months Reasons to Buy Assists in formulating key business strategies with regards to investment Helps in identifying prominent locations for conducting clinical trials which saves time and cost Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities Supports understanding of trials count and enrollment trends by country in global therapeutics market Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials Facilitates clinical trial assessment of the indication on a global, regional and country level Key Topics Covered: Clinical Trials Report Coverage Clinical Trials by Region Clinical Trials and Average Enrollment by Country Top Five Countries Contributing to Clinical Trials in Asia-Pacific Top Five Countries Contributing to Clinical Trials in Europe Top Countries Contributing to Clinical Trials in North America Top Five Countries Contributing to Clinical Trials in Middle East and Africa Top Countries Contributing to Clinical Trials in Central and South America Clinical Trials by G7 Countries: Proportion of Burkitt Lymphoma to Oncology Clinical Trials Clinical Trials by Phase in G7 Countries Clinical Trials in G7 Countries by Trial Status Clinical Trials by E7 Countries: Proportion of Burkitt Lymphoma to Oncology Clinical Trials Clinical Trials by Phase in E7 Countries Clinical Trials in E7 Countries by Trial Status Clinical Trials by Phase In Progress Trials by Phase Clinical Trials by Trial Status Clinical Trials by End Point Status Subjects Recruited Over a Period of Time Clinical Trials by Sponsor Type Prominent Sponsors Top Companies Participating in Burkitt Lymphoma Therapeutics Clinical Trials Prominent Drugs Clinical Trial Profile Snapshots Abbreviations Company Coverage: Bristol-Myers Squibb Co Pfizer Inc Takeda Pharmaceutical Co Ltd Roche Holding AG Amgen Inc Gilead Sciences Inc Merck & Co Inc Novartis AG Sanofi Sian Wuhan Medical Technology Co Ltd For more information about this clinical trials report visit https://www.researchandmarkets.com/r/c5m5c6 About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

DORAL, Fla.--(BUSINESS WIRE)--Dec 23, 2024-- NeueHealth, Inc. (“NeueHealth” or the “Company”) (NYSE: NEUE), the value-driven healthcare company, today announced that it has entered into a definitive merger agreement pursuant to which the Company will be acquired by an affiliate of New Enterprise Associates (“NEA”) at an enterprise value of approximately $1.3 billion. Upon completion of the transaction, NeueHealth will become a privately held company with the flexibility and resources to continue advancing its value-driven, consumer-centric care model. Under the terms of the merger agreement, holders of NeueHealth common stock (other than shares that will be rolled over and certain excluded shares) will receive $7.33 per share in cash, which represents a premium of approximately 70% over the closing price of NeueHealth common stock on December 23, 2024. Certain stockholders of NeueHeath, including NEA and 12 existing NeueHealth investors (which collectively hold all of the outstanding shares of NeueHealth preferred stock), have entered into rollover agreements pursuant to which such stockholders will continue their investments by exchanging their shares of NeueHealth common stock and/or preferred stock for newly issued equity interests in the privately held company, and the Company’s existing secured loan facility with Hercules Capital, Inc. will remain in place. NeueHealth’s executive leadership team will continue in their roles upon completion of the transaction and intends to roll over 100% of their equity interests for newly issued equity interests in the privately held company. “We are pleased to announce this transaction as we believe it places NeueHealth in a strong position for continued growth while maximizing value for all of NeueHealth’s public stockholders,” said Mike Mikan, President and CEO of NeueHealth. “NEA has been a longstanding strategic partner, and we look forward to continuing to work together to build on NeueHealth’s success as a leader in value-based care.” “We believe NeueHealth has built a differentiated model of care that is uniquely positioned to drive value for consumers, providers, and payors and we have confidence in the NeueHealth team and their ability to continue to lead the Company,” said Mohamad Makhzoumi, Co-CEO of NEA. “We have had a strong partnership with NeueHealth since 2016 and share the Company’s commitment to making high-quality healthcare accessible and affordable for all Americans.” Transaction Details A special committee (the “Special Committee”) of the board of directors of NeueHealth (the “Board”), composed entirely of independent and disinterested directors and advised by its own independent legal and financial advisors, unanimously recommended that the Board approve the transaction and determined it was in the best interests of the Company and its stockholders that are not affiliated with NEA. Acting upon the recommendation of the Special Committee, the Board subsequently unanimously approved the transaction and determined to recommend that NeueHealth stockholders vote to approve and adopt the merger agreement. Certain NeueHealth stockholders have agreed to vote all of their shares of NeueHealth common stock and/or preferred stock to approve and adopt the merger agreement, subject to certain conditions. The merger is subject to approval by NeueHealth’s stockholders and other customary closing conditions, including receipt of certain regulatory approvals. NEA intends to finance the transaction with fully committed equity financing, and the transaction is not subject to any financing condition. Upon completion of the transaction, NeueHealth’s common stock will no longer be publicly traded or listed on any public market. The merger agreement includes a 30-day “go-shop” period that will expire at 12:01 AM New York City time on January 23, 2025, which permits the Special Committee and its financial advisors to solicit and consider alternative acquisition proposals. There can be no assurance that this process will result in a superior proposal, and NeueHealth does not intend to disclose developments with respect to the “go-shop” process unless and until it determines such disclosure is appropriate or is otherwise required. Lincoln International, LLC is acting as financial advisor, and Richards, Layton & Finger, P.A. is acting as legal counsel, to the Special Committee. Simpson Thacher & Bartlett LLP is acting as legal counsel to NeueHealth. Latham and Watkins LLP is acting as legal counsel to NEA, with Sidley Austin LLP acting as insurance regulatory counsel to NEA. More information regarding the key terms will be included in a current report on Form 8-K to be filed by NeueHealth with the Securities and Exchange Commission (the “SEC”). Important Information and Where to Find It In connection with the transaction, the Company will file with the SEC a proxy statement on Schedule 14A (the “Proxy Statement”), the definitive version of which will be sent or provided to Company stockholders. The Company, affiliates of the Company and affiliates of NEA intend to jointly file a transaction statement on Schedule 13E-3 (the "Schedule 13E-3") with the SEC. The Company may also file other documents with the SEC regarding the transaction. This release is not a substitute for the Proxy Statement, the Schedule 13E-3 or any other document which the Company may file with the SEC. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE PROXY STATEMENT, THE SCHEDULE 13E-3 AND ANY OTHER RELEVANT DOCUMENTS THAT ARE FILED OR WILL BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY BEFORE MAKING ANY VOTING OR INVESTMENT DECISION WITH RESPECT TO THE COMPANY OR THE TRANSACTION BECAUSE THESE DOCUMENTS CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION ABOUT THE TRANSACTION AND RELATED MATTERS. Investors and security holders may obtain free copies of the Proxy Statement, the Schedule 13E-3 and other documents that are filed or will be filed with the SEC by the Company, when such documents become available, through the website maintained by the SEC at www.sec.gov or through the Company's website at https://investors.neuehealth.com/home/default.aspx . The transaction will be implemented solely pursuant to the Agreement and Plan of Merger, dated as of December 23, 2024 (the “merger agreement”), among the Company, NH Holdings 2025, Inc. and NH Holdings Acquisition 2025, Inc., which contains the full terms and conditions of the transaction. Participants in the Solicitation The Company and certain of its directors, executive officers and employees may be deemed to be participants in the solicitation of proxies from stockholders of the Company in connection with the proposed transaction. Information regarding the Company’s directors and executive officers is available in the definitive proxy statement for the 2024 annual meeting of stockholders of the Company, which was filed by the Company with the SEC on April 1, 2024 (the “Annual Meeting Proxy Statement”), and will be available in the Proxy Statement. Please refer to the sections captioned “Executive Compensation,” “Director Compensation,” and “Security Ownership of Certain Beneficial Owners and Management” in the Annual Meeting Proxy Statement. Holdings of the Company’s securities by certain of the Company’s employees, and any changes in the holdings of the Company’s securities by the Company’s directors or executive officers from the amounts described in the Annual Meeting Proxy Statement, have been reflected in the following Statements of Change in Ownership on Form 4 filed with the SEC: Form 4, filed by George Lawrence Mikan III on May 6, 2024; Form 4, filed by Jay Matushak on May 6, 2024; Form 4, filed Tomas Orozco on May 6, 2024; Form 4, filed by Jeffery Michael Craig on May 6, 2024; Form 4, filed by Jeffrey J. Scherman on May 6, 2024; Form 4, filed by Jay Matushak on May 13, 2024; Form 4, filed by Jeffrey J. Scherman on May 13, 2024; Form 4, filed by Kedrick D. Adkins, Jr. on May 14, 2024; Form 4, filed by Andrew M. Slavitt on May 14, 2024; Form 4, filed by Linda Gooden on May 14, 2024; Form 4, filed by Mohamad Makhzoumi on May 14, 2024; Form 4, filed by Robert J. Sheehy on May 14, 2024; Form 4, filed by Matthew G. Manders on May 14, 2024; Form 4, filed by Stephen Kraus on May 14, 2024; Form 4, filed by Manuel Kadre on May 14, 2024; Form 4, filed by Jeffrey R. Immelt on May 14, 2024; Form 4, filed by Mohamad Makhzoumi on October 3, 2024; Form 4, filed by Jay Matushak on October 8, 2024; Form 4, filed by George Lawrence Mikan III on December 18, 2024. Other information regarding the participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, will be contained in the Proxy Statement and other relevant materials to be filed with the SEC in connection with the proposed transaction when they become available. Free copies of the Proxy Statement and such other materials may be obtained as described in the preceding paragraph. About NeueHealth NeueHealth is a value-driven healthcare company grounded in the belief that all health consumers are entitled to high-quality, coordinated care. By uniquely aligning the interests of health consumers, providers, and payors, NeueHealth helps to make healthcare accessible and affordable to all populations across the ACA Marketplace, Medicare, and Medicaid. NeueHealth delivers high-quality clinical care to over 500,000 health consumers through owned clinics and unique partnerships with over 3,000 affiliated providers. We also enable independent providers and medical groups to thrive in performance-based arrangements through a suite of technology and services scaled centrally and deployed locally. We believe our value-driven, consumer-centric care model can transform the healthcare experience and maximize value across the healthcare system. For more information, visit: www.neuehealth.com . About NEA New Enterprise Associates (NEA) is a global venture capital firm focused on helping entrepreneurs build transformational businesses across multiple stages, sectors and geographies. Founded in 1977, NEA has more than $25 billion in assets under management as of June 30, 2024 and invests in technology and healthcare companies at all stages in a company’s lifecycle, from seed stage through IPO. The firm's long track record of investing includes more than 280 portfolio company IPOs and more than 465 mergers and acquisitions. For more information, please visit www.nea.com . Forward-Looking Statements This release contains certain “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements made in this release that are not statements of historical fact, including statements about our beliefs and expectations, are forward-looking statements and should be evaluated as such. Forward-looking statements include information concerning possible or assumed future results of operations, including descriptions of our business plan and strategies, and statements as to the expected timing, completion and effects of the transaction. These statements often include words such as “anticipate,” “expect,” “plan,” “believe,” “intend,” “project,” “forecast,” “estimates,” “projections,” “outlook,” “ensure,” and other similar expressions. These forward-looking statements include any statements regarding our plans, expectations and financial guidance. Such forward-looking statements are subject to various risks, uncertainties and assumptions. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. Factors that might materially affect such forward-looking statements include: the failure to complete the transaction on the anticipated terms and within the anticipated timeframe, including as a result of failure to obtain required stockholder or regulatory approvals or to satisfy other closing conditions; potential litigation relating to the transaction that could be instituted against NEA, the Company or their respective affiliates, directors, managers, officers or employees, and the effects of any outcomes related thereto; potential adverse reactions or changes to our business relationships or operating results resulting from the announcement, pendency or completion of the transaction; the risk that our stock price may decline significantly if the transaction is not consummated; certain restrictions during the pendency of the transaction that may impact our ability to pursue certain business opportunities or strategic transactions; costs associated with the transaction, which may be significant; the occurrence of events, changes or other circumstances that could give rise to the termination of the merger agreement, including in circumstances requiring us to pay a termination fee; our ability to continue as a going concern; our ability to comply with the terms of our credit facilities­ or any credit facility into which we enter in the future; our ability to receive the remaining proceeds from the sale of our Medicare Advantage business in California in a timely manner; our ability to obtain any short or long term debt or equity financing needed to operate our business; our ability to quickly and efficiently complete the wind down of our remaining Individual and Family Plan (“IFP”) and MA businesses, including by satisfying liabilities of those businesses when due and payable; potential disruptions to our business due to the transaction or due to corporate restructuring and any resulting headcount reduction; our ability to accurately estimate and effectively manage the costs relating to changes in our business offerings and models; a delay or inability to withdraw regulated capital from our subsidiaries; a lack of acceptance or slow adoption of our business model; our ability to retain existing consumers and expand consumer enrollment; our and our care partner’s abilities to obtain and accurately assess, code, and report risk adjustment factor scores; our ability to contract with care providers and arrange for the provision of quality care; our ability to obtain claims information timely and accurately; the impact of any pandemic or epidemic on our business and results of operations; the risks associated with our reliance on third-party providers to operate our business; the impact of modifications or changes to the U.S. health insurance markets; our ability to manage any growth of our business; our ability to operate, update or implement our technology platform and other information technology systems; our ability to retain key executives; our ability to successfully pursue acquisitions, integrate acquired businesses, and quickly and efficiently divest businesses as needed; the occurrence of severe weather events, catastrophic health events, natural or man-made disasters, and social and political conditions or civil unrest; our ability to prevent and contain data security incidents and the impact of data security incidents on our members, patients, employees and financial results; our ability to comply with requirements to maintain effective internal controls; our ability to adapt to mitigate risks associated with our ACO businesses, including any unanticipated market or regulatory developments; and the other factors set forth under the heading “Risk Factors” in the Company’s reports on Form 10-K, Form 10-Q, and Form 8-K (including all amendments to those reports) and our other filings with the SEC. Except as required by law, we undertake no obligation to update publicly any forward-looking statements for any reason after the date of this release to conform these statements to actual results or changes in our expectations. View source version on businesswire.com : https://www.businesswire.com/news/home/20241223595862/en/ CONTACT: Investor Contact: IR@neuehealth.comMedia Contact: media@neuehealth.com KEYWORD: FLORIDA UNITED STATES NORTH AMERICA INDUSTRY KEYWORD: PRACTICE MANAGEMENT PROFESSIONAL SERVICES MANAGED CARE HEALTH GENERAL HEALTH HEALTH TECHNOLOGY HEALTH INSURANCE HOSPITALS INSURANCE TELEMEDICINE/VIRTUAL MEDICINE FINANCE SOURCE: NeueHealth Copyright Business Wire 2024. PUB: 12/23/2024 05:53 PM/DISC: 12/23/2024 05:53 PM http://www.businesswire.com/news/home/20241223595862/en